Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncologist. 2007 Jul;12(7):756-65.

Lapatinib-associated toxicity and practical management recommendations.

Author information

  • 1Massachusetts General Hospital Cancer Center, Gillette Center for Women's Cancers, Lawrence House, LRH 304, Boston, MA 02114, USA. bmoy@partners.org

Abstract

Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.

PMID:
17673607
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk